Patents by Inventor Carmine D'urzo

Carmine D'urzo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS USING SERPIN PRODUCING BACTERIA
    Publication number: 20230210920
    Abstract: Serpin protein producing Bifidobacterium longum subsp. longum and compositions thereof for use in inhibiting gluten digestion. Compositions comprising the serpin protein producing Bifidobacterium longum subsp. longum may be used to mitigate the effects of hidden gluten in individuals following a gluten free diet.
    Type: Application
    Filed: May 11, 2021
    Publication date: July 6, 2023
    Inventors: TIAGO ALVES NUNES, GABRIELA BERGONZELLI DEGONDA, STEPHANE DUBOUX, PETER DUNCAN, CARMINE D'URZO, ELENA VERDU DE BERCIK
  • Method for treating Philadelphia-negative myeloproliferative syndromes
    Patent number: 8217079
    Abstract: Method for treating Philadelphia-negative myeloproliferative syndromes in a patient in need of such treatment, by administering to the patient diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride or other pharmaceutically acceptable salts and/or solvates thereof, in combination with N-hydroxyurea.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: July 10, 2012
    Assignee: Italfarmaco SpA
    Inventors: Paolo Mascagni, Carmine D'urzo, Joseê Golay
  • Method for treating Philadelphia-negative myeloproliferative syndromes
    Publication number: 20110237663
    Abstract: A method for treating Philadelphia-negative myeloproliferative syndromes (polycythemia vera, essential thrombocythemia or idiopathic myelofibrosis) which comprises administering diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride or other pharmaceutically acceptable salts and/or solvates thereof, in combination with N-hydroxyurea to a patient in need of such a treatment, is described. The diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride in combination with N-hydroxyurea induces positive therapeutic responses in patients refractory to the N-hydroxyurea monotherapy and/or whose therapeutic response to monotherapy with the same dose of N-hydroxyurea is unsatisfactory.
    Type: Application
    Filed: March 26, 2010
    Publication date: September 29, 2011
    Applicant: ITALFARMACO SPA
    Inventors: Paolo Mascagni, Carmine D'urzo, Joseê Golay